Bank of America (FEED) amends ENvue stake, flags dilution risk
Filing Impact
Filing Sentiment
Form Type
3/A
Rhea-AI Filing Summary
Bank of America and affiliates filed an amended Form 3/A for ENvue Medical, Inc., updating the reported event date to January 30, 2026 and confirming 10% owner status. The filing reports indirect beneficial ownership of 234,056 shares of common stock through subsidiaries BANA and BOFAS.
The disclosure relies on 1,088,192 outstanding shares as of December 5, 2025, as stated in a December 18, 2025 prospectus, which covers the resale of up to 7,962,279 shares of common stock and notes that additional issuances could materially increase outstanding shares and substantially dilute existing stockholders.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
BANK OF AMERICA CORP /DE/, BOFA SECURITIES, INC., BANK OF AMERICA NA
Role
10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 234,056 shares (Indirect, See Footnotes)
Footnotes (1)
- The determination of 10% Owner relies on the 1,088,192 outstanding shares disclosed in the Form 424B3 - Prospectus by the issuer on December 18, 2025, which reports share totals as of December 5, 2025. The prospectus pertains to the resale, from time to time, by selling stockholders of up to 7,962,279 shares of common stock. While not yet finalized, the issuance of additional shares could materially increase the number of outstanding common shares and result in substantial dilution to existing stockholders. This statement is jointly filed by Bank of America, BANA and BOFAS. Bank of America holds an indirect interest in the securities listed in Table I ("the Securities") by virtue of its indirect ownership of its subsidiaries, BANA and BOFAS. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
FAQ
What does Bank of America’s amended Form 3/A for ENvue Medical (FEED) disclose?
The amended Form 3/A discloses that Bank of America and its subsidiaries indirectly beneficially own 234,056 ENvue Medical common shares and are treated as 10% owners. It also corrects the date of the reportable event to January 30, 2026.
Why is Bank of America considered a 10% owner of ENvue Medical (FEED)?
The 10% owner status relies on 1,088,192 outstanding ENvue shares disclosed in a December 18, 2025 prospectus, which reports totals as of December 5, 2025. Based on this share count, the reported 234,056 indirectly owned shares exceed the 10% threshold.
What potential dilution does the ENvue Medical (FEED) prospectus describe?
The referenced prospectus covers the resale, from time to time, of up to 7,962,279 ENvue common shares by selling stockholders. It notes that issuance of additional shares could materially increase outstanding common shares and result in substantial dilution to existing stockholders.
Who are the reporting persons in the ENvue Medical (FEED) Form 3/A filing?
The statement is jointly filed by Bank of America, BANA and BOFAS. Bank of America’s interest in the ENvue securities arises indirectly through its ownership of BANA and BOFAS, and all three entities are listed as reporting persons in the filing.
What disclaimer about group status is included in the ENvue Medical (FEED) Form 3/A?
Each reporting person states that the filing should not be construed as an admission of acting as a partnership, syndicate, or other group, or as a member of any group, for purposes of acquiring, holding, or disposing of ENvue Medical securities.